Table 2. The global prevalence of anxiety in HIV/AIDS patients base on the questionnaire, type of study and quality of study.

Subgroups		Number Studies	Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity
			Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Questionnaire	ASI-3	1	0.449	0.367	0.533
	BAI	8	0.352	0.277	0.434	-3.449	0.001	93.36	7	<0.001	92.50
	DASS_21	1	0.273	0.208	0.350
	GAD	5	0.216	0.121	0.355	-3.661	<0.001	239.45	4	<0.001	98.33
	HADS	17	0.192	0.143	0.254	-7.904	<0.001	794.78	16	<0.001	97.99
	HARS	1	0.110	0.069	0.169
	ICD-10	2	0.105	0.021	0.397	-2.434	0.015	24.88	1	<0.001	95.98
	IDAS	1	0.609	0.503	0.706
	SAS	1	0.470	0.409	0.532
	Unknown	3	0.503	0.335	0.671	0.035	0.972	54.88	2	<0.001	96.36
Type of study	Cohort	9	0.168	0.100	0.269	-5.217	<0.001	471.23	8	<0.001	98.30
	Cross-sectional	31	0.292	0.248	0.340	-7.782	<0.001	966.43	30	<0.001	96.90
Quality of study	High	23	0.206	0.157	0.265	-7.976	<0.001	1405.31	22	<0.001	98.43
	Low	6	0.298	0.188	0.437	-2.774	0.006	97.05	5	<0.001	94.85
	Medium	11	0.359	0.295	0.430	-3.835	<0.001	165.39	10	<0.001	93.95